CA3142877A1 - Telmisartan for the treatment of chronic kidney disease in dogs - Google Patents

Telmisartan for the treatment of chronic kidney disease in dogs Download PDF

Info

Publication number
CA3142877A1
CA3142877A1 CA3142877A CA3142877A CA3142877A1 CA 3142877 A1 CA3142877 A1 CA 3142877A1 CA 3142877 A CA3142877 A CA 3142877A CA 3142877 A CA3142877 A CA 3142877A CA 3142877 A1 CA3142877 A1 CA 3142877A1
Authority
CA
Canada
Prior art keywords
telmisartan
period
mmhg
treatment
daily dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142877A
Other languages
English (en)
French (fr)
Inventor
Anne Michelle Traas
Amanda Erickson Coleman
Bianca Natalia Ferreira De Moura Lourenco
Kate Elizabeth CREEVY
Scott Alan Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
University of Georgia Research Foundation Inc
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
University of Georgia Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, University of Georgia Research Foundation Inc filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of CA3142877A1 publication Critical patent/CA3142877A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3142877A 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs Pending CA3142877A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962871749P 2019-07-09 2019-07-09
US62/871,749 2019-07-09
PCT/US2020/030581 WO2021006942A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of hypertension in dogs

Publications (1)

Publication Number Publication Date
CA3142877A1 true CA3142877A1 (en) 2021-01-14

Family

ID=70775532

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142877A Pending CA3142877A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs

Country Status (11)

Country Link
US (1) US12605366B2 (enExample)
EP (1) EP3996709A1 (enExample)
JP (2) JP2022540077A (enExample)
KR (1) KR20220054292A (enExample)
CN (1) CN114173777A (enExample)
AU (2) AU2020310059B2 (enExample)
BR (1) BR112022000398A2 (enExample)
CA (1) CA3142877A1 (enExample)
MX (1) MX2022000426A (enExample)
TW (1) TW202116306A (enExample)
WO (1) WO2021006942A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1023027B (de) 1953-07-10 1958-01-23 Hoffmann La Roche Verfahren zur Herstellung von Polyendialdehyden
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4448778A (en) 1981-08-03 1984-05-15 Ici Americas Inc. Maltitol containing gel base systems
GB8401500D0 (en) 1984-01-20 1984-02-22 Johnson Matthey Plc Measurement of physiological parameter
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
DE3807672A1 (de) 1988-03-09 1989-09-21 Vectron Ges Fuer Technologieen Verfahren zum kontinuierlichen messen des blutdrucks am menschen und blutdruckmessgeraet zum durchfuehren des verfahrens
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0443983B1 (de) 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
TW201738B (enExample) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US6028091A (en) 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
GB9027210D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
US5331162A (en) 1991-11-22 1994-07-19 Trw Inc. Sensitive, low-noise superconducting infrared photodetector
HUT71331A (en) 1992-04-13 1995-11-28 Zeneca Ltd Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
JP3862295B2 (ja) 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
EP0754042A4 (en) 1994-03-29 2004-06-23 Merck & Co Inc TREATING ATHEROSCLEROSIS WITH IMIDAZOLES BLOCKING THE ANGIOTENSIN II RECEPTOR
KR19980703647A (ko) 1995-04-07 1998-12-05 베르너발데크 베나제프릴 또는 베나제프릴라트 및 발사르탄을 함유하는조성물
CA2257946A1 (en) 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
JPH11315034A (ja) 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
WO1999044590A1 (en) 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE19901921C2 (de) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
US6331162B1 (en) 1999-02-01 2001-12-18 Gary F. Mitchell Pulse wave velocity measuring device
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US6516209B2 (en) 2000-08-04 2003-02-04 Photonify Technologies, Inc. Self-calibrating optical imaging system
US6801648B2 (en) 2000-08-04 2004-10-05 Xuefeng Cheng Optical imaging system with symmetric optical probe
US7510728B2 (en) 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
JP3785529B2 (ja) 2000-12-06 2006-06-14 カシオ計算機株式会社 血圧測定システム及び血圧値演算装置
JP2005501815A (ja) 2001-05-14 2005-01-20 メルク　エンド　カムパニー　インコーポレーテッド 治療方法
JP2004536834A (ja) 2001-07-06 2004-12-09 オークランド ユニサーヴィシズ リミテッド 高血圧症治療
EP1413315A4 (en) 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004019876A2 (en) 2002-08-28 2004-03-11 Curis, Inc. Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
WO2005070463A2 (en) 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
DE102004008804A1 (de) 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8005624B1 (en) 2004-04-26 2011-08-23 Starr Life Sciences Corp. Medical devices and techniques for rodent and small mammalian based research
WO2005123070A1 (en) 2004-06-09 2005-12-29 Fibrogen, Inc. Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy
CN100364532C (zh) 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
PL1814527T5 (pl) 2004-11-05 2021-08-02 Boehringer Ingelheim International Gmbh Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę
US20070026026A1 (en) 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
US20090005361A1 (en) 2006-02-06 2009-01-01 Randy Lee Webb Combination of Organic Compounds
CN100413464C (zh) 2006-05-26 2008-08-27 中国人民解放军空军航空医学研究所 在脉搏波法动脉血压连续测量中的脉搏波传导时间的获取方法和装置
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
JP4925284B2 (ja) 2006-10-26 2012-04-25 パナソニック株式会社 健康測定装置
US20080183232A1 (en) 2007-01-30 2008-07-31 Voss Gregory I Method and system for determining cardiac function
EP1970053A1 (en) 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
JP2008237686A (ja) 2007-03-28 2008-10-09 Sanyo Electric Co Ltd 伸縮可能センサ及び該センサを用いた体調管理装置
US11076772B2 (en) 2007-03-30 2021-08-03 David G. Silverman Method and system enabling photoplethysmograph measurement of volume status
US20110260176A1 (en) 2008-05-12 2011-10-27 Pioneer Corporation Light-emitting sensor device and method for manufacturing the same
EP2349478A4 (en) 2008-10-16 2012-04-25 Carl Frederick Edman METHOD AND DEVICES FOR AUTOMATICALLY ADJUSTING A PHOTOTHERAPEUTIC INTERVENTION
WO2010065067A1 (en) 2008-11-20 2010-06-10 Bodymedia, Inc. Method and apparatus for determining critical care parameters
CA2653011A1 (en) 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
JP5326792B2 (ja) 2009-05-14 2013-10-30 ソニー株式会社 静脈撮像装置、位置ズレ補間方法およびプログラム
AU2010251194B2 (en) 2009-05-20 2016-02-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical oral telmisartan solution
US20130030259A1 (en) 2009-12-23 2013-01-31 Delta, Dansk Elektronik, Lys Og Akustik Monitoring system
JP5234078B2 (ja) 2010-09-29 2013-07-10 株式会社デンソー 脈波解析装置および血圧推定装置
AU2012211300A1 (en) 2011-01-27 2013-05-09 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for monitoring the circulatory system
US8838209B2 (en) 2012-02-21 2014-09-16 Xerox Corporation Deriving arterial pulse transit time from a source video image
US9216000B2 (en) 2012-05-03 2015-12-22 Vioptix, Inc. Light wavelength selection for avoidance of surgical dyes
WO2015127193A1 (en) 2014-02-20 2015-08-27 Faurecia Automotive Seating, Llc. Vehicle seat with integrated sensors
EP3160346A1 (en) 2014-06-27 2017-05-03 Koninklijke Philips N.V. Animal vital sign detection system
US20160045117A1 (en) 2014-08-14 2016-02-18 Nehemiah T. Liu Peak Detection System and Method for Calculation of Signal-Derived Metrics
KR102411658B1 (ko) 2015-01-15 2022-06-21 삼성전자주식회사 생체 정보 검출 장치
WO2016141330A1 (en) 2015-03-05 2016-09-09 Palo Alto Investors Homeostatic capacity evaluation
EP3307069B1 (en) 2015-06-10 2021-08-04 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
JP2017000415A (ja) 2015-06-10 2017-01-05 セイコーエプソン株式会社 情報取得装置および情報取得方法
US10292658B2 (en) 2015-06-23 2019-05-21 Rochester Institute Of Technology Apparatus, system and method for medical analyses of seated individual
KR102434698B1 (ko) 2015-07-03 2022-08-22 삼성전자주식회사 생체 정보 검출 장치 및 방법
US20180199824A1 (en) 2015-07-10 2018-07-19 Bodyport Inc. Device for measuring biological signals
JP6593176B2 (ja) 2016-01-04 2019-10-23 オムロンヘルスケア株式会社 血圧補正情報生成装置、血圧測定装置、血圧補正情報生成方法、血圧補正情報生成プログラム
US20170188963A1 (en) 2016-01-05 2017-07-06 Tosense, Inc. Physiological monitoring system featuring floormat and handheld sensor
WO2017142240A1 (en) 2016-02-18 2017-08-24 Samsung Electronics Co., Ltd. Method and electronic device for cuff-less blood pressure(bp) measurement
US20170245767A1 (en) 2016-02-25 2017-08-31 Echo Labs, Inc. Systems and methods for modified pulse transit time measurement
EP3422944A4 (en) 2016-03-03 2019-08-14 Dynometrics Inc. D/B/A Humon TISSUE DETERGENT RECOGNITION AND RELATED DEVICE AND METHOD
EP3435855B1 (en) 2016-03-29 2023-05-10 The Board of Trustees of the Leland Stanford Junior University Proximity sensor circuits and related sensing methods
KR101950555B1 (ko) 2016-03-30 2019-02-20 순천향대학교 산학협력단 스마트 체중계를 이용한 부정맥을 포함한 생체신호 측정 시스템
US10271745B2 (en) 2016-06-17 2019-04-30 Qualcomm Incorporated Monolithic integrated emitter-detector array in a flexible substrate for biometric sensing
KR20190050784A (ko) 2016-09-07 2019-05-13 사니오나 에이/에스 테소펜신 조성물
EP3537962A4 (en) 2016-11-10 2019-11-27 Auburn University METHOD AND SYSTEM FOR ASSESSING BLOOD VESSELS
CN106949951A (zh) 2017-05-04 2017-07-14 北京沃凡思智选家居科技有限公司 智能体重秤
US20180360323A1 (en) 2017-06-20 2018-12-20 Heartisans Limited Method for monitoring blood pressure, and a device thereof
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
CN111954488B (zh) 2018-03-08 2024-08-06 生物隐形有限公司 心血管健康监测装置
WO2019206818A1 (en) 2018-04-23 2019-10-31 Evonik Degussa Gmbh Methods to estimate the blood pressure and the arterial stiffness based on photoplethysmographic (ppg) signals
US11857299B2 (en) 2018-12-27 2024-01-02 Polar Electro Oy Wearable heart activity sensor device
CN110251105B (zh) 2019-06-12 2022-06-21 广州视源电子科技股份有限公司 一种无创血压测量方法、装置、设备及系统
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs
BR112022000315A2 (pt) 2019-07-09 2022-02-22 Boehringer Ingelheim Vetmedica Gmbh Telmisartana para o tratamento da doença renal crônica em cães
TWI882018B (zh) 2019-10-17 2025-05-01 德商百靈佳殷格翰維美迪加股份有限公司 用於動物醫學檢查之方法及檢查裝置及相關電腦程式及電腦可讀儲存媒體
CA3154960A1 (en) 2019-10-17 2021-04-22 Boehringer Ingelheim Vetmedica Gmbh Examination apparatus for medical examination of an animal
AU2024276892A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
TW202541793A (zh) 2023-12-15 2025-11-01 德商百靈佳殷格翰維美迪加股份有限公司 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑

Also Published As

Publication number Publication date
MX2022000426A (es) 2022-04-25
EP3996709A1 (en) 2022-05-18
AU2020310059B2 (en) 2026-04-30
US12605366B2 (en) 2026-04-21
US20220226290A1 (en) 2022-07-21
CN114173777A (zh) 2022-03-11
KR20220054292A (ko) 2022-05-02
BR112022000398A2 (pt) 2022-03-03
JP2025115405A (ja) 2025-08-06
AU2020310059A1 (en) 2022-02-17
WO2021006942A1 (en) 2021-01-14
AU2026202684A1 (en) 2026-04-30
JP2022540077A (ja) 2022-09-14
TW202116306A (zh) 2021-05-01

Similar Documents

Publication Publication Date Title
CA2665435C (en) Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
AU2026202684A1 (en) Telmisartan for the treatment of hypertension in dogs
US20250195525A1 (en) Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats
JP2025120167A (ja) イヌの慢性腎臓病の治療のためのテルミサルタン
US20190008831A1 (en) Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
RU2830555C2 (ru) Телмисартан для лечения гипертонии у собак
RU2832966C2 (ru) Телмисартан для лечения хронической болезни почек у собак
AU2013203932B2 (en) Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
AU2007304216B9 (en) Angiotensin II receptor antagonist for the treatment of systemic diseases in cats

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240321

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250321

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250422

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250721

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260420

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20260715

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260715

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20260715

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260720